Drug pipeline 2Q23 — controversy and complexity

Drug pipeline 2Q23 — controversy and complexity

The US Food and Drug Administration (FDA) verdict on Sarepta’s Elevidys, a gene therapy delivering microdystrophin to patients with DMD, proved to be the most controversial decision of the quarter. The company teased positive efficacy from the data for patients aged 4–5 but not for older peers, with Sarepta’s fervent promise of data by the fall from a randomized trial in that narrow patient band clinching an accelerated approval. The FDA also approved another complex therapy, Seres Therapeutics’ Wowst, the first oral microbiome therapy for recalcitrant Clostridioides difficile–associated diarrhea. At the more structurally defined end of the spectrum, Pfizer’s inhibitor of coronavirus 3C-like-proteinase, Paxlovid, became the first oral antiviral approved for the treatment of COVID-19 infections. Between the extremes of complexity falls Krystal Biotech’s Vyjuvek, a redosable gene therapy for the severe skin disorder dystrophic epidermolysis bullosa, caused by inherited deficiencies in collagen VII: Vyjuvek is the first approved topically applied gene therapy and the first based on herpes simplex virus-1 (HSV-1). The impending 2023 Northern Hemisphere respiratory disease season will see the availability of two adult vaccines for respiratory syncytial virus (RSV) infections, with the back-to-back approvals of two products based on stabilized pre-fusion F protein subunit: GSK’s Arexvy and Pfizer’s Abrysvo. As the quarter came to a close, the FDA approved the first cell therapy for type 1 diabetes, CellTrans’s Lantidra (allogeneic deceased donor pancreas–derived islets of Langerhans) and the first gene therapy for hemophilia A, Roctavian.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

209,00 € per year

only 17,42 € per issue

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact customer support

Author information

Authors and Affiliations

Cambridge, UK

John Hodgson

About this article

Cite this article

Hodgson, J. Drug pipeline 2Q23 — controversy and complexity.
Nat Biotechnol (2023). https://doi.org/10.1038/s41587-023-01886-6

Download citation

Published: 27 July 2023

DOI: https://doi.org/10.1038/s41587-023-01886-6

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-023-01886-6

Exit mobile version